Key facts
- Waiv’s last known valuation is $499.1M (Mar 2026).
- It has raised $32.9M; the latest was Early Stage VC ($32.9M) in Mar 2026.
- Notable investors include Serena, OTB Ventures, Alpha Intelligence Capital, Karista (Paris), SISTAFUND.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Waiv
- ·The full record, as it builds
Funding rounds
No funding rounds for Waiv are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Waiv
Developer of artificial intelligence-based diagnostic tests designed to support precision oncology and biomarker-driven medicine. The company applies machine learning and foundation models to histopathology and multimodal clinical data, offering AI-enabled biomarker discovery, risk and outcome prediction, treatment-response assessment, and workflow integration with pathology and oncology systems, enabling healthcare providers and biopharmaceutical companies to conduct scalable, data-driven testing that supports targeted therapies, clinical decision-making, and streamlined diagnostic pathways across oncology.
- Sector
- Healthcare
- HQ
- Paris, France
- Website
- wearewaiv.com/
- Ownership
- Privately Held (backing)
Waiv doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Waiv shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Waiv in its N-PORT filings yet. We sweep new filings monthly.